European Society of Cardiology (ESC) Congress 2021

CV safety of degarelix vs leuprolide: Results remain inconclusive

Roshini Claire Anthony, 20211006180001

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

1-month DAPT may be enough post-PCI

Elvira Manzano, 20211006000000

In patients at high-bleeding risk (HBR) implanted with a drug-eluting coronary stent, 1 month of dual antiplatelet therapy (DAPT) is as good as 3 months or longer – with significantly less bleeding – in the MASTER DAPT* trial, that experts said shorter DAPT post coronary stenting may be the strategy moving forward.

FIGARO-DKD: Finerenone CV benefit extends to wide spectrum of CKD patients with T2D

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD

Pearl Toh, 20210925150000

The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone, in addition to its renal benefit, across a wide spectrum of patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

BP target in older Chinese: How low can clinicians go?

Elvira Manzano, 20210922000000

Under 130 mm Hg – that’s how low clinicians can go in terms of systolic blood pressure (SBP) to reduce cardiovascular events in older, hypertensive Chinese patients, suggests the multicentre STEP* trial.

Salt substitute may slash stroke risk

Roshini Claire Anthony, 20210920160001

Swapping regular salt for a reduced-sodium salt substitute may cut stroke, major adverse cardiovascular event (MACE)*, and death rates in individuals with a risk of stroke, according to results of the SSaSS** trial.

Quadpill trumps monotherapy in BP lowering

Pearl Toh, 20210918150000

A quadruple combination containing quarter doses of four blood pressure (BP)-lowering drugs in a single pill — termed a quadpill — led to better BP control than using monotherapy for initial treatment of hypertension, according to the QUARTET study presented at ESC 2021.

Flu vaccine cuts all-cause, CV death risk in cardiac patients

Roshini Claire Anthony, 20210917180001

Receiving an influenza vaccination after hospitalization for an invasive coronary procedure or a myocardial infarction (MI) may reduce the risk of all-cause or cardiovascular (CV) death, according to results of the IAMI* trial.

Binge drinking in early adulthood linked to increased arterial stiffness

Elaine Soliven, 20210917000000

Alcohol consumption during late adolescence and early adulthood was associated with increased arterial stiffness, which may lead to future cardiovascular events, according to a study presented at ESC 2021.

CVD risk increases with intake of saturated fats from meat

Elvira Manzano, 20210916000000

Regular intake of saturated fatty acids (SFA) from meat could increase cardiovascular disease (CVD) risk whereas dairy sources, grains, fruits, and vegetables could be cardio-protective, suggests a study in the UK.

Empagliflozin reduces CV death or HHF in HFpEF

Christina Lau, 20210916000000

Empagliflozin significantly reduces the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) vs placebo in patients with heart failure with preserved ejection fraction (HFpEF) with or without diabetes, according to results of the EMPEROR-Preserved trial presented at the European Society of Cardiology (ESC) Congress 2021.